Cambridge University biotech spin-out Definigen has secured £1.3m ($2.13m) in series A funding in a round led by the university’s tech transfer unit Cambridge Enterprise, and joined by early-stage investor 24Haymarket and Cambridge-based biotech Abcam’s co-founder Jonathan Milner.
Cambridge Enterprise’s involvement marks the largest investment made by the university through its seed funds in a single round to date, weighing in at £525,000.
Founded in April last year, Definigen is commercialising stem cell technology developed at Cambridge, and is one…
